Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Trazenta, Amoxicillin and Others under PMDA Risk Review
September 26, 2017
- Interdepartmental Cooperation Needed to Treat Symptoms Following HPV Vaccination: MHLW Panels
September 26, 2017
- MHLW to Urge Drug Makers to Create Systems to Prevent Improper Promotional Activities: Official
September 25, 2017
- MHLW Panel Approves Increase in Raw Plasma Allocation to Nihon Pharmaceutical to 350,000 Liters
September 22, 2017
- Kaketsuken in Talks with “Several Entities” over Possible Biz Transfer: New Chief
September 21, 2017
- MHLW to Consider Use of New Comprehensive Test System to Promote Practical Use of Genomic Medicine for Cancer: Official
September 21, 2017
- MHLW Issues Notification on Drug Criteria for Optimal Use Guidelines
September 20, 2017
- Japan Drug Spending Logs 1st Fall in FY2016
September 19, 2017
- MHLW Begins Discussions towards Submission of Bill to Amend Pharma Law in 2019: Official
September 19, 2017
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
- Chuikyo Working to Craft ICER Yardstick for Pilot CEA Scheme; Shiroiwa Study Leading Candidate among WTP Cost Surveys?
September 14, 2017
- Chuikyo Ponders How to Deal with ICER for Products with Multiple Indications
September 14, 2017
- Samurai Biotech Association Calls for NHI Price Increases When Sales Fall Below Forecasts: Chuikyo
September 14, 2017
- JGA President Sees Reduction in Number of Generic Drug Makers as “Inevitable”: Chuikyo
September 14, 2017
- With 253 Billion Yen Estimate Out, Chuikyo Members Prod MHLW to Vet Impact of Price Maintenance Premium
September 14, 2017
- JPWA Expresses Concern Over Price Renegotiations, Calls for Guidelines to Curb Practice
September 14, 2017
- (Update) Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW to Notify of Criteria for Drugs Subject to Optimal Use Guidelines in Mid-September
September 13, 2017
- Similar “Treatment” Comparison Method Could Be Up for Discussion as New Pricing Scheme: Chuikyo
September 13, 2017
- MHLW Calls for Reduction in Maximum Administration Period and Total Dosage for Feron
September 13, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…